Inspired by scientific advancements from the lab to clinical settings, 7 Primus Biosciences, Inc. develops innovative anti-cancer medications that surpass current therapies.
Our goal is to provide cancer patients with unprecedented clinical benefits in a timely manner.
Our main focus is the Bak molecule, a pro-apoptotic effector located on the outer membrane of mitochondria.
Activating Bak is a crucial step in initiating apoptosis, which leads to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and ultimately apoptosis.
Our lead compound, 7PB-100, is a first-in-class small molecule Bak activator with powerful anti-proliferative effects on NSCLC and SCLC xenografts, SCLC PDX, and genetically engineered RASG12D animal models. It achieves this while causing minimal toxicity to normal tissues. Additionally, it shows a significant synergistic effect with the Bcl-2 inhibitor venetoclax against lung cancer, offering a new treatment option due to its unique mode of action.
To support the company's growth, we are seeking seed capital to advance our program. We would greatly appreciate the opportunity to present ourselves in more detail to your team.
We look forward to your prompt response.
Yours sincerely,
Hahn-Jun Lee, M.Sc., Ph.D.
Founder/CEO
Ready to Ask For Funding for your company?
Post a Funding Request